MAP2K7 and melanoma: BRAF/MEK inhibition reprograms metabolism in melanoma, involving a decrease in glycolysis [13] and a compensatory increase in oxidative phosphorylation that is mediated at least in part by a MITF-PGC1A pathway [14,39].